A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Status:
Recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether the study drug, SDX-7320, when
combined with the standard chemotherapy eribulin, is an effective treatment for people with
TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment
(SDX-7320 combined with eribulin) is safe and causes few or mild side effects in
participants. The researchers will compare this treatment approach to eribulin alone.